COVID-19 vaccines developed in the USA will not be registered until November

COVID-19 vaccines being developed in the USA will not be registered until late November. This was reported on Thursday, August 13, citing the head of the U.S. National Institute of Health Francis Collins.

According to him, potential vaccines supported by the Trump Warp Speed program are unlikely to get the green light from the regulators before November-December due to the need for large-scale clinical trials.

Collins added that involving about 10,000 volunteers in the experiments would gather enough information on the safety and efficacy of the drugs for widespread use.

The head of the U.S. National Institutes of Health is confident that at least one of the six vaccines funded under the program will be shown to be safe and effective by the end of the year.

Collins expects that the first tens of millions of doses of the vaccine produced in the United States will be given to those who need it most, such as patients at higher risk of complications or health care providers.

The U.S. government has provided $1.2 billion to the British-Swedish pharmaceutical company AstraZeneca, which is developing the vaccine together with scientists from Oxford University (UK). The Washington administration also allocated $486 million to the American biotechnology company Moderna and $456 million to the pharmaceutical company Johnson & Johnson. Creation of coronavirus vaccine in the U.S. is also conducted by Merck and Pfizer. According to the White House, the administration has invested a total of $12 billion in the development of the coronavirus vaccine.